Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Multicenter three-year results after combined cataract surgery and supraciliary microstent implantation for open-angle glaucoma

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Sunday 11/09/2016 | 15:00-16:30

Paper Time: 15:50

Venue: Poster Village: Pod 3

First Author: : H.Höh GERMANY

Co Author(s): :    S. Grisanti   S. Grisanti   A. Anton   C. Erb   P. Guguchkova   J. Garcia-Feijoo

Abstract Details

Purpose:

Evaluate the safety and efficacy of supraciliary microstent implantation in conjunction with cataract surgery, including rate of adverse events, changes in intraocular pressure (IOP) and use of glaucoma medications (meds) at 3 years follow-up.

Setting:

Multicenter European clinical study

Methods:

Multicenter prospective interventional case series (CyCLE study). Investigators performed standard small-incision cataract surgery followed by implantation of the CyPass Micro-Stent (Transcend Medical, Inc, Menlo Park, CA) into the supraciliary space through the phaco incision.

Results:

No major adverse events, such as choroidal hemorrhage, hypotony maculopathy, or retinal detachment, occurred in the 36M follow-up period. Mean IOP was 19.8 mmHg at baseline (n=269) and 16.5 mmHg at 36M (n=169). In patients with uncontrolled IOP (≥ 21 mmHg) at baseline (n=102), mean IOP decreased from 25.4 + 5.1 mmHg at baseline to 17.1 + 3.8 mmHg at 36M, representing a paired IOP reduction of 29%. 87% of patients did not need additional IOP-lowering surgery. In all patients, average medication use reduced 2.1 at baseline to 1.3 medications at 36M.

Conclusions:

The 3-year safety profile of the CyPass Micro-Stent gives long-term evidence of its compatibility with cataract surgery and the potential to employ this therapy earlier in the glaucoma treatment paradigm as compared with conventional surgery. CyPass Micro-Stent implantation is a minimally invasive intervention for the treatment of open-angle glaucoma that spares the conjunctiva, sclera and trabecular meshwork, can be performed in conjunction with small-incision cataract surgery, and shows sustained control of IOP and decreased need for glaucoma meds in eyes 3 years postoperatively.

Financial Disclosure:

One or more of the authors gains financially from competing product or procedure, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors gains financially from product or procedure presented

Back to previous